CervoMed Inc. announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16(th) Clinical Trials in Alzheimer's Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts. Details for the CTAD 2023 Oral Presentation Title: A Phase 2b Clinical Trial of Neflamapimod in Dementia with Lewy Bodies Designed to Confirm the Efficacy Results from Phase 2a Date /Time: October 25, 2023 /2:50 p.m. ET Presenter: Niels Prins, MD, PhD, Chief Executive Officer of Brain Research Center - Amsterdam Session Title: OC8 - ORAL COMMUNICATIONS.